Post hoc analysis, using the final dataset from ORAL Surveillance, reveals a higher risk of non-serious infections and herpes zoster with tofacitinib vs TNFi, and higher risk of serious infection events with tofacitinib 10 mg BID versus TNFi, particularly in patients aged ≥65 years.
Following preliminary safety results from the ORAL Surveillance trial. Balanescu, et al. sought to compare infections in patients with RA receiving tofacitinib versus TNFi, and to identify risk factors for infections in these patients, using the final dataset.
The authors recommend that the results from this study should be carefully considered as part of shared decision-making between physicians and patients.